Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Short Interest Down 37.4% in June

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) was the target of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 1,609,679 shares, a decrease of 37.4% from the May 31st total of 2,572,499 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average trading volume of 1,385,421 shares, the days-to-cover ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

CNTA has been the topic of several research analyst reports. B. Riley Financial lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their price objective for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Finally, Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price on the stock. in a research report on Monday, April 13th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $41.33.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Virtus Investment Advisers LLC raised its stake in shares of Centessa Pharmaceuticals by 6.2% during the 4th quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock worth $251,000 after purchasing an additional 583 shares during the period. Coastal Bridge Advisors LLC raised its position in Centessa Pharmaceuticals by 7.1% in the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after acquiring an additional 931 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after acquiring an additional 979 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $25,000. Finally, Wells Fargo & Company MN grew its position in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares during the period. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock remained flat at $40.50 during trading hours on Thursday. The firm has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. The stock has a fifty day moving average of $39.81 and a two-hundred day moving average of $31.92. Centessa Pharmaceuticals has a fifty-two week low of $12.74 and a fifty-two week high of $40.56. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, research analysts forecast that Centessa Pharmaceuticals will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.